Immune Checkpoint Inhibitor-Associated Myocarditis: A Run of Bad Luck or Rather Deficient-Monitoring Protocol?

CMR CMR, cardiac magnetic resonance ICI, immune checkpoint inhibitor LGE, late gadolinium enhancement LV, left ventricular LVEF, left ventricular ejection fraction MMF, mycophenolate mofetil NSCLC, non–small cell lung cancer PD, programmed death PD-L, programmed death-ligand RR, reference range VT, ventricular tachycardia irAE irAE, immune-related adverse event myocarditis pembrolizumab ventricular tachycardia

Journal

JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 09 10 2019
revised: 23 12 2019
accepted: 26 12 2019
entrez: 28 7 2021
pubmed: 15 4 2020
medline: 15 4 2020
Statut: epublish

Résumé

Immune checkpoint inhibitors (ICIs) can induce immunity-related adverse events. We demonstrate the clinical use of cardiac magnetic resonance and endomyocardial biopsy in the diagnosis and subsequent monitoring of ICI-associated myocarditis, suggesting the need to establish and evaluate a cardiac monitoring protocol for patients under ICI therapy. (

Identifiants

pubmed: 34317309
doi: 10.1016/j.jaccas.2019.12.047
pii: S2666-0849(20)30146-7
pmc: PMC8298681
doi:

Types de publication

Case Reports

Langues

eng

Pagination

630-635

Informations de copyright

© 2020 The Authors.

Références

J Cancer Res Clin Oncol. 2019 Jun;145(6):1527-1557
pubmed: 31028541
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219
Heart. 2008 Nov;94(11):1456-63
pubmed: 18230640
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Circulation. 2005 Apr 12;111(14):1784-91
pubmed: 15809378
Haematologica. 2018 Jul;103(7):e318-e321
pubmed: 29650641
Circulation. 2008 Apr 1;117(13):1745-9
pubmed: 18378628
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Clin Res Cardiol. 2017 Jul;106(7):560-563
pubmed: 28321496
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870

Auteurs

Grigorios Chatzantonis (G)

Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.

Georg Evers (G)

Department of Medicine A, Hematology, Oncology and Pulmonary Medicine, University Hospital Münster, Münster, Germany.

Claudia Meier (C)

Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.

Michael Bietenbeck (M)

Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.

Anca Florian (A)

Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.

Karin Klingel (K)

Division of Cardiopathology, Institute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.

Annalen Bleckmann (A)

Department of Medicine A, Hematology, Oncology and Pulmonary Medicine, University Hospital Münster, Münster, Germany.

Ali Yilmaz (A)

Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Münster, Münster, Germany.

Classifications MeSH